Civetta Therapeutics Names Roberts as CEO
2 September 2021 - - US-based biotechnology company Civetta Therapeutics, LLC has appointed Christopher D. Roberts, Ph.D. as chief executive officer, the company said.

Dr. Roberts, who most recently served as chief scientific officer of Black Diamond Therapeutics, brings more than 20 years of experience discovering and developing novel therapies for oncology, immunology, virology and other indications.

Cameron Wheeler, Ph.D., who was serving as chief executive officer at Civetta and is a partner in the Biotherapeutics Group at Deerfield Management Company, will continue to serve as chairman of Civetta's board of directors.

Prior to joining Black Diamond, Roberts served as an Entrepreneur in Residence at SR One, the corporate venture capital arm of GlaxoSmithKline (NYSE: GSK).

Prior to SR One, Chris was the vice president of Chemistry and Early Development at Syros Pharmaceuticals, Inc., a publicly traded biotechnology company focused on gene control and drugging transcription, where he built and led a range of discovery and development functions and helped guide two oncology assets into clinical development.

Prior to joining Syros, Chris held numerous positions of increasing responsibility at GSK, including VP and Head of the Host Defense Discovery Performance Unit, and also led multiple clinical development projects.

He joined GSK as Senior director of Hepatitis C Virus Medicinal Chemistry via its acquisition of Genelabs Technologies. As a medicinal chemist at Genelabs, Chris was significantly involved in establishing Genelabs' HCV research focus. His work has been extensively published.

Civetta is a biotechnology company focused on the development of therapies that target beta-propeller domains to treat cancer and other diseases.

Civetta is funded by Deerfield Management company and is based in Cambridge, MA.